Evidence map›Paper›PMID 37499893›Full record

ArticleAmerican journal of ophthalmology2023

Assessing Change in Exudative Age-Related Macular Degeneration With Macular Thickness Maps as a Surrogate Strategy for Remote Patient Monitoring.

Omer Trivizki, Masha Varcheie, Simon Bello, Ian Raden, Prashanth Iyer, Marlyn Marquez, Amina Chaudhry, Alaa Al-Dabbagh, Giovanni Gregori, Philip J Rosenfeld

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Omer TrivizkiFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA; Department of Ophthalmology, Tel Aviv Medical Center, University of Tel Aviv (O.T.), Tel Aviv, Israel.
Masha VarcheieCarl Zeiss Meditec, Inc. (M.V., S.B., I.R.), Dublin, California, USA.
Simon BelloCarl Zeiss Meditec, Inc. (M.V., S.B., I.R.), Dublin, California, USA.
Ian RadenCarl Zeiss Meditec, Inc. (M.V., S.B., I.R.), Dublin, California, USA.
Prashanth IyerFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA.
Marlyn MarquezFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA.
Amina ChaudhryFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA.
Alaa Al-DabbaghFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA.
Giovanni GregoriFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA.
Philip J RosenfeldFrom the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (O.T., P.I., M.M., A.C., A.A.-D., G.G., P.J.R.), Miami, Florida, USA. Electronic address: prosenfeld@miami.edu.
University of Miami · USCarl Zeiss (United States) · US

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Dmitry V Ivanov · 2004 to 2026
$12.2M
NEI NIH HHS P30 EY014801
6 · The paper itself

Abstract

purposeTo determine if macular thickness maps (MTMs) are sufficient to guide management of eyes with exudative age-related macular degeneration (eAMD), we compared the ability to detect change using MTMs with the ability to detect change using the entire optical coherence tomography (OCT) scan in patients undergoing therapy.

designRetrospective, comparative diagnostic analysis.

methodsPatients with eAMD were imaged using macula-centered 6 × 6-mm OCT scans (CIRRUS HD-OCT 5000; Zeiss). In each case, graders were asked to determine if there were changes that warranted a full clinical assessment after viewing 2 consecutive scans using one of 3 different imaging strategies: MTMs alone, individual foveal-centered B scans alone, or 5 macular B scans including the foveal-centered B scan. Graders were told the 2 scans were taken 2 weeks apart. The consensus ground truth was reached by the graders using a CIRRUS review station to evaluate all the information contained within the OCT scans.

resultsA total of 53 eyes were included in this study with 1385 imaging sessions. The Fleiss kappa was highest when graders were given MTMs alone compared with the ground truth. When the averages of all 5 graders were compared with the ground truth, the MTMs alone showed the highest level of agreement (90.05%, SD 0.78%) followed by the central B scans (87.87%, SD 1.59%) and the 5-B scan method (86.512%, SD 0.64%).

conclusionMTMs alone provide sufficient information to easily identify recurrent exudation in patients with eAMD, and these maps may be all that is needed for remote monitoring.

Indexed as

Macula LuteaMacular DegenerationFovea CentralisHumansRetrospective StudiesTomography, Optical Coherence

Identifiers

PMID37499893
PMCPMC10808271
OpenAlexW4385259652

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.